MUC1 Vaccines, Comprised of Glycosylated or Non-Glycosylated Peptides or Tumor-Derived MUC1, Can Circumvent Immunoediting to Control Tumor Growth in MUC1 Transgenic Mice
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
MUC1 Vaccines, Comprised of Glycosylated or Non-Glycosylated Peptides or Tumor-Derived MUC1, Can Circumvent Immunoediting to Control Tumor Growth in MUC1 Transgenic Mice
Authors
Keywords
T cells, Vaccination and immunization, Vaccines, Mouse models, Major histocompatibility complex, Immune response, Flow cytometry, Glycosylation
Journal
PLoS One
Volume 11, Issue 1, Pages e0145920
Publisher
Public Library of Science (PLoS)
Online
2016-01-21
DOI
10.1371/journal.pone.0145920
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Boost and loss of immune responses against tumor-associated antigens in the course of pregnancy as a model for allogeneic immunotherapy
- (2014) M. Lutz et al. BLOOD
- Preclinical Evidence That PD1 Blockade Cooperates with Cancer Vaccine TEGVAX to Elicit Regression of Established Tumors
- (2014) J. Fu et al. CANCER RESEARCH
- Targeting DNGR-1 (CLEC9A) with antibody/MUC1 peptide conjugates as a vaccine for carcinomas
- (2014) Gianfranco Picco et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- PD-1 identifies the patient-specific CD8+ tumor-reactive repertoire infiltrating human tumors
- (2014) Alena Gros et al. JOURNAL OF CLINICAL INVESTIGATION
- Progression of Pancreatic Adenocarcinoma Is Significantly Impeded with a Combination of Vaccine and COX-2 Inhibition
- (2014) P. Mukherjee et al. JOURNAL OF IMMUNOLOGY
- Emerging Principles for the Therapeutic Exploitation of Glycosylation
- (2014) Martin Dalziel et al. SCIENCE
- Immune checkpoints
- (2014) Akhil Chawla et al. OncoImmunology
- Aberrant Expression of Mucin Core Proteins and O-Linked Glycans Associated with Progression of Pancreatic Cancer
- (2013) N. Remmers et al. CLINICAL CANCER RESEARCH
- Up to 15-year clinical follow-up of a pilot Phase III immunotherapy study in stage II breast cancer patients using oxidized mannan–MUC1
- (2013) Stamatis Vassilaros et al. Immunotherapy
- Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial
- (2013) Charles Butts et al. LANCET ONCOLOGY
- Nonclassical Antigen-Processing Pathways Are Required for MHC Class II-Restricted Direct Tumor Recognition by NY-ESO-1-Specific CD4+ T Cells
- (2013) J. Matsuzaki et al. Cancer Immunology Research
- Phase 1 dose escalation of ONT-10, a therapeutic MUC1 vaccine, in patients with advanced cancer
- (2013) John Nemunaitis et al. Journal for ImmunoTherapy of Cancer
- MUC1 Vaccine for Individuals with Advanced Adenoma of the Colon: A Cancer Immunoprevention Feasibility Study
- (2012) T. Kimura et al. Cancer Prevention Research
- Abstract 762: ONT-10, a liposomal vaccine targeting hypoglycosylated MUC1, induces a potent cellular and humoral response and suppresses the growth of MUC1 expressing tumors
- (2012) Linda A. Pestano et al. CANCER RESEARCH
- MUC1 immunotherapy is here to stay
- (2012) Takashi Kimura et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- The Thymic Niche Does Not Limit Development of the Naturally Diverse Population of Mouse Regulatory T Lymphocytes
- (2012) P. Romagnoli et al. JOURNAL OF IMMUNOLOGY
- Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival
- (2012) Steffen Walter et al. NATURE MEDICINE
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- (2012) Suzanne L. Topalian et al. NEW ENGLAND JOURNAL OF MEDICINE
- Local Effects of Regulatory T Cells in MUC1 Transgenic Mice Potentiate Growth of MUC1 Expressing Tumor Cells In Vivo
- (2012) Daisuke Sugiura et al. PLoS One
- Clinical Evaluation of TRICOM Vector Therapeutic Cancer Vaccines
- (2012) Ravi A. Madan et al. SEMINARS IN ONCOLOGY
- MUC1-Specific Cytotoxic T Lymphocytes in Cancer Therapy: Induction and Challenge
- (2012) David Roulois et al. Biomed Research International
- Prevention of colitis-associated colon cancer using a vaccine to target abnormal expression of the MUC1 tumor antigen
- (2012) Pamela Beatty et al. OncoImmunology
- Widespread CD4+ T-cell reactivity to novel hTERT epitopes following vaccination of cancer patients with a single hTERT peptide GV1001
- (2012) Else-Marit Inderberg-Suso et al. OncoImmunology
- Pancreatic Ductal Adenocarcinoma Mice Lacking Mucin 1 Have a Profound Defect in Tumor Growth and Metastasis
- (2011) D. M. Besmer et al. CANCER RESEARCH
- Therapeutic vaccination with TG4010 and first-line chemotherapy in advanced non-small-cell lung cancer: a controlled phase 2B trial
- (2011) Elisabeth Quoix et al. LANCET ONCOLOGY
- Immune recognition of tumor-associated mucin MUC1 is achieved by a fully synthetic aberrantly glycosylated MUC1 tripartite vaccine
- (2011) V. Lakshminarayanan et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Cancer Immunoediting: Integrating Immunity's Roles in Cancer Suppression and Promotion
- (2011) R. D. Schreiber et al. SCIENCE
- Tumor Antigen Epitopes Interpreted by the Immune System as Self or Abnormal-Self Differentially Affect Cancer Vaccine Responses
- (2010) S. O. Ryan et al. CANCER RESEARCH
- The Prioritization of Cancer Antigens: A National Cancer Institute Pilot Project for the Acceleration of Translational Research
- (2009) M. A. Cheever et al. CLINICAL CANCER RESEARCH
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now